Abstract Development of monoclonal antibodies (mAbs) and their functional derivatives
represents a growing segment of the development pipeline in the pharmaceutical industry …

The influence of drug-receptor binding kinetics has often been overlooked during the
development of new therapeutics that target G protein-coupled receptors (GPCRs). Over the …

Abstract Models for drugs exhibiting target-mediated drug disposition (TMDD) play an
important role in the investigation of biological products (Mager and Jusko 2001). These …

Nonlinear pharmacokinetics and pharmacodynamics may result from several capacity-
limited processes and often represent complicating factors in characterizing the …

Target‐mediated drug disposition (TMDD) is the phenomenon in which a drug binds with
high affinity to its pharmacological target site (such as a receptor) to such an extent that this …

It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate
constant of target dissociation is a major determinant of the time course and duration of in …

Monoclonal antibodies (mAbs) are currently the largest and most dominant class of
therapeutic proteins. Inter-individual variability has been observed for several mAbs; …

Target‐mediated drug disposition (TMDD) is a term to describe a nonlinear pharmacokinetic
(PK) phenomenon that is caused by high‐affinity binding of a compound to its …

An important feature of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD)
models is the identification of drug-and system-specific factors that determine the intensity …

Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates
decision making during drug discovery, and increases the probability of success for early …